654 related articles for article (PubMed ID: 33117402)
21. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19.
Mrityunjaya M; Pavithra V; Neelam R; Janhavi P; Halami PM; Ravindra PV
Front Immunol; 2020; 11():570122. PubMed ID: 33117359
[TBL] [Abstract][Full Text] [Related]
22. Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS.
Lupu L; Palmer A; Huber-Lang M
Front Immunol; 2020; 11():584514. PubMed ID: 33101314
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
[TBL] [Abstract][Full Text] [Related]
24. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
[TBL] [Abstract][Full Text] [Related]
25. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Wu D; Yang XO
J Microbiol Immunol Infect; 2020 Jun; 53(3):368-370. PubMed ID: 32205092
[TBL] [Abstract][Full Text] [Related]
26. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 and COVID-19: From the Bench to the Bedside.
Romagnoli S; Peris A; De Gaudio AR; Geppetti P
Physiol Rev; 2020 Oct; 100(4):1455-1466. PubMed ID: 32496872
[TBL] [Abstract][Full Text] [Related]
28. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322
[TBL] [Abstract][Full Text] [Related]
29. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.
Soto M; diZerega G; Rodgers KE
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972018. PubMed ID: 33169644
[TBL] [Abstract][Full Text] [Related]
30. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.
Martin TR; Wurfel MM; Zanoni I; Ulevitch R
EBioMedicine; 2020 Jul; 57():102836. PubMed ID: 32574958
[TBL] [Abstract][Full Text] [Related]
31. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.
Arnaldez FI; O'Day SJ; Drake CG; Fox BA; Fu B; Urba WJ; Montesarchio V; Weber JS; Wei H; Wigginton JM; Ascierto PA
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385146
[TBL] [Abstract][Full Text] [Related]
32. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
[TBL] [Abstract][Full Text] [Related]
33. Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets.
Karmouty-Quintana H; Thandavarayan RA; Keller SP; Sahay S; Pandit LM; Akkanti B
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138181
[TBL] [Abstract][Full Text] [Related]
34. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
Theoharides TC
Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
[No Abstract] [Full Text] [Related]
35. Cytokine storm intervention in the early stages of COVID-19 pneumonia.
Sun X; Wang T; Cai D; Hu Z; Chen J; Liao H; Zhi L; Wei H; Zhang Z; Qiu Y; Wang J; Wang A
Cytokine Growth Factor Rev; 2020 Jun; 53():38-42. PubMed ID: 32360420
[TBL] [Abstract][Full Text] [Related]
36. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
Dalamaga M; Karampela I; Mantzoros CS
Metabolism; 2020 Aug; 109():154282. PubMed ID: 32497535
[TBL] [Abstract][Full Text] [Related]
37. COVID-19: lambda interferon against viral load and hyperinflammation.
Andreakos E; Tsiodras S
EMBO Mol Med; 2020 Jun; 12(6):e12465. PubMed ID: 32333818
[TBL] [Abstract][Full Text] [Related]
38. The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe?
Abassi Z; Knaney Y; Karram T; Heyman SN
Front Immunol; 2020; 11():1312. PubMed ID: 32582222
[TBL] [Abstract][Full Text] [Related]
39. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
40. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes.
Bonafè M; Prattichizzo F; Giuliani A; Storci G; Sabbatinelli J; Olivieri F
Cytokine Growth Factor Rev; 2020 Jun; 53():33-37. PubMed ID: 32389499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]